Showing results (31-40 of 990) with videos related to
Sort By:
Pageof 99
Statistical Methods in Medical Research|February 21, 2008
Surrogate endpoint validation: statistical elegance versus clinical relevanceEm Green, G Yothers, Daniel J SargentJournal of Biopharmaceutical Statistics|April 23, 2009
Current issues in oncology drug development, with a focus on Phase II trialsDaniel J Sargent, Jeremy M G TaylorJournal of the American Statistical Association|February 15, 2011
CAUSAL EFFECTS OF TREATMENTS FOR INFORMATIVE MISSING DATA DUE TO PROGRESSION/DEATHKeunbaik Lee, Michael J Daniels, Daniel J SargentStatistics in Medicine|October 4, 2006
An adaptive phase I design for identifying a biologically optimal dose for dual agent drug combinationsSumithra J Mandrekar, Yue Cui, Daniel J SargentClinical Medicine Insights. Oncology|May 24, 2011
Systemic therapy for elderly patients with gastrointestinal cancerJoleen M Hubbard, Axel Grothey, Daniel J SargentJournal of Biopharmaceutical Statistics|June 7, 2014
Impact of Copula Directional Specification on Multi-Trial Evaluation of Surrogate End PointsLindsay A Renfro, Hongwei Shang, Daniel J SargentTransactions of the American Clinical and Climatological Association|August 11, 2010
Leveraging learning from a phase III colorectal cancer clinical trial: outcomes, methodology, meta-analysis and pharmacogeneticsRichard M Goldberg, Daniel J Sargent, Howard McLeodStatistics in Medicine|April 27, 2010
Model-based phase I designs incorporating toxicity and efficacy for single and dual agent drug combinations: methods and challengesSumithra J Mandrekar, Rui Qin, Daniel J SargentJournal of the National Cancer Institute|November 9, 2014
DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147)Adam M Lee, Qian Shi, Emily Pavey, et al.Biometrics|August 16, 2011
Bayesian adaptive trial design for a newly validated surrogate endpointLindsay A Renfro, Bradley P Carlin, Daniel J SargentPageof 99